Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2024-09-25 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
This has reference to the email of BSE dated September 25, 2024. We wish to inform that we have no information/announcement including pending announcement which in the Company''s opinion ....
Regulatory Filings Classification · 100% confidence The document is a letter responding to a regulatory inquiry from BSE Surveillance regarding an increase in trading volume. It states that the company has no information or pending announcements that could affect the stock price or volume. The letter references compliance with SEBI Listing Obligations and Disclosure Requirements. The document is short (946 characters) and is a regulatory communication rather than a financial report or announcement of a report. It does not contain financial data, management changes, voting results, or other specific report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications.
2024-09-25 English
This is to inform that the Company has received permission for sale and distribution of Durvalumab 120mg/2.4 ml and 500mg/10 ml solution for infusion (Imfinzi) from the Central Drugs Standard ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It informs about the receipt of permission from a regulatory authority (Central Drugs Standard Control Organisation) for the import and sale of a pharmaceutical product with an additional indication. The content is an intimation or announcement of a regulatory or business development rather than a financial report, earnings release, or management discussion. The document length is short (1801 characters) and does not contain financial data or detailed report content. It fits best as a Regulatory Filing (RNS), which is a general category for regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-09-23 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It informs about AstraZeneca Pharma India Limited receiving permission from a regulatory authority (Central Drugs Standard Control Organisation) for an additional indication of a drug. The content is an intimation or announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is short (1801 characters) and it serves as a notification to the stock exchanges rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance documents that do not fit other specific categories.
2024-09-23 English
We refer to our earlier communication dated June 1, 2023, intimating the receipt of Import and Market permission in Form CT-20 from Drugs Controller General of India for Tremelimumab (Imjudo) ....
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to stock exchanges (BSE and NSE) regarding the launch of a pharmaceutical product, Tremelimumab (Imjudo), by AstraZeneca Pharma India Limited. It references a prior communication about regulatory approval but primarily serves as an update on the product launch timing. There are no financial statements, earnings data, management discussion, or regulatory filings related to financial performance. The document is brief (1423 characters) and is an announcement to the exchanges rather than a detailed report or filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings related to financial disclosures. It is an operational update communicated to the stock exchanges, which aligns best with the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-09-20 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding the launch of a pharmaceutical product, Tremelimumab (Imjudo), by AstraZeneca Pharma India Limited. It references a prior communication about regulatory approval (Form CT-20) and provides an update on the product launch timeline. The content is an announcement related to business operations and product launch, not a financial report, earnings release, or regulatory filing about financials or governance. The document length is short (1423 characters), and it does not contain financial data, management discussion, or voting results. It is not a report or presentation but an official communication to stock exchanges about a business update. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-20 English
Please find enclosed the letter of the Company in relation to the captioned subject.
Legal Proceedings Report Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to stock exchanges. It informs about a final assessment order received from the Income Tax Department related to the assessment year 2021-22. The document includes details of a legal/tax dispute and mentions that the matter will be challenged before the Income-tax Appellate Tribunal. There are no financial statements or detailed financial analysis present, and the document is primarily an announcement of a regulatory/legal development. This fits the category of a Legal Proceedings Report (LTR) as it updates on significant legal matters involving the company.
2024-09-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.